Elicio Therapeutics’ KRAS pancreatic cancer vaccine fails in Phase 2, stock drops sharply

Elicio Therapeutics reported that its KRAS‑targeted vaccine for pancreatic cancer did not improve patient outcomes in a mid‑stage (Phase 2) trial. The study results were released in a company statement and indicated no statistical benefit over the control group.

Following the announcement, Elicio’s share price fell sharply as investors reacted to the negative readout. The company said it will continue to explore the program and is looking for additional financing to potentially advance the vaccine into a larger Phase 3 trial.

Elicio did not disclose any new efficacy data or safety concerns beyond the lack of improvement. The firm’s next steps will depend on its ability to raise capital and on regulatory feedback regarding a possible Phase 3 design.

The setback highlights the challenges of developing KRAS‑directed immunotherapies for pancreatic cancer, a disease with historically low response rates to treatment.